Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. (linkinghub.elsevier.com)

Authors: Sarraju A … Nissen SE Journal: The Lancet Published: 2026-08-28 DOI: https://doi.org/10.1016/S0140-6736(26)01484-4